Polymethoxyflavones
(PMFs) are a subgroup of flavonoids possessing
various health benefits. 3,5,7,4′-Tetramethoxyflavone (1), 5,6,7,4′-tetramethylflavone (2), 3,7,3′,4′-tetramethoxyflavone
(3), 5,7,3′,4′-tetramethoxyflavone (4), 5-hydroxy-3,7,2′,4′-tetramethoxyflavone
(5), 3,5,7,2′,4′-pentamethoxyflavone (6), 5-hydroxy-3,7,3′,4′-tetramethoxyflavone
(7), 3-hydroxy-5,7,3′,4′-tetramethylflavone
(8), 3,5,7,3′,4′-pentamethoxyflavone (9), 5-hydroxy-3,7,3′,4′,5′-pentamethoxyflavone
(10), 3-hydroxy-5,7,3′,4′,5′-pentamethoxyflavone
(11), and 3,5,7,3′,4′,5′-hexamethoxylflavone
(12) were 12 bioactive and available PMFs. The aim of
this study was to investigate the pharmacokinetic, metabolite, and
antitumor activities as well as the structure–pharmacokinetic–antitumor
activity relationships of these 12 PMFs to facilitate further studies
of their medicinal potentials. The cytotoxicity of PMFs with a hydroxy
group toward HeLa, A549, HepG2, and HCT116 cancer cell lines was generally
significantly more potent than that of PMFs without a hydroxy group.
Compounds 5, 7, 8, 10, and 11 were all undetectable in rat plasma, while
compounds 1–4, 6, 9, and 12 were detectable. Both the number and
position of hydroxy and methoxy groups played an important role in
modulating PMF pharmacokinetics and metabolites.